In conclusion, we identified TNFRSF18, TNFSF4, and IL12RB2 as biomarkers that predict response to NK cell therapeutics by studying the tumor immune microenvironment using NanoString and qRT-PCR analyses in patients with recurrent GBM who received activated NK cell treatment. This evidence concerns the gene TNFRSF18 and neoplasm.